BigBear.ai Holdings Inc · NYSE · Cash-burning thematic defense-AI bet
Real defense-AI contracts, but revenue fell 19% into the AI wave while shares tripled — priced at ~19x shrinking sales with a restatement overhang.
What it does. BigBear.ai sells AI-powered decision-intelligence and data-analytics software, mostly to US government, defense, and intelligence customers (force management, biometrics, geopolitical-risk and supply-chain analysis), with a smaller commercial slice.
Is it making or burning money? Burning. It has real revenue but has never been profitable as a public company. FY2025 (year ended 2025-12-31) revenue was $127.672M — down about 19% from $158.236M in FY2024 — with an operating loss of -$213.897M and a net loss of -$293.914M (both larger than the company's entire annual revenue). Operating cash flow was -$41.951M in FY2025, the fifth straight year of cash burn.
Why it could be interesting. US defense-AI spending is a genuine, law-backed wave (the FY2026 NDAA authorized large RDT&E budgets), and BBAI has some real anchors: a 5-year sole-source Army production franchise (GFIM-OE), a fresh $53M sole-source classified prime award lifting backlog to $281.9M, and the Ask Sage GenAI-SaaS acquisition (closed 2025-12-31, ~$25M ARR, 100K+ government users) that could bolt recurring revenue onto a lumpy services book.
The ONE big risk. The story is growth, but the audited numbers show contraction plus a relentless dilution treadmill — shares went from ~157M (end-2023) to ~437M (end-2025) to 477M (2026-03-31), roughly tripling in just over two years — so even a real recovery has to overcome a share count that keeps climbing. Layered on top: an accounting restatement back to FY2021 and two pending securities class actions.
What you'd be betting on (risk-framed): That backlog actually converts, Ask Sage scales, losses inflect toward breakeven, and dilution slows — all of which must go right at once for a stock already priced at ~19x shrinking sales. If any one slips, the same rich multiple that creates the upside can halve the stock.
## Demand Thesis: Real Wave, But BBAI Catches Only a Sliver
Is the wave real? Yes, with high conviction. The FY2026 NDAA (signed 2025-12-18) authorized ~$146B in DoD RDT&E, with $13.4B earmarked for autonomy and AI-driven systems in the FY2026 budget request — this is authorized doctrine, not a forecast. The Pentagon has shifted from piloting AI to operationalizing it (Palantir's Maven is now a program of record). The CDAO funds prototype contracts that can become production follow-ons, and border/trade modernization (CBP, TSA, FAA) is natural BBAI territory given McAleenan's DHS background.
How big / how fast for BBAI specifically? This is where the thesis narrows. The structural demand is real, but BBAI's own top line moved the WRONG way through it: FY2025 revenue fell to $127.672M from $158.236M in FY2024 — a ~19% decline — and Q1 2026 revenue of $34.4M was still down ~1% YoY. The wave lifted peers (Palantir, C3.ai) while BBAI contracted, partly attributed to Army program timing and DOGE-related federal disruptions the CEO publicly acknowledged. BBAI's slice is constrained by customer concentration (a secondary source, Iceberg Research, alleges ~49% of 2023 revenue from 3 clients — not independently confirmable from the fact sheet) and lumpy, program-dependent revenue.
Big player vs. commodity? BBAI is structurally a niche, program-dependent contractor, not a platform company. Its most credible lever to become a bigger player is Ask Sage (GenAI SaaS, ~$25M ARR growing ~6x YoY, 100K+ government users) — a real on-ramp toward recurring, higher-margin platform economics. But at a ~$250M acquisition price against ~$25M ARR, payback is long and execution/integration risk is high. International (UAE/AD Ports) and the Panama/ISC cargo deployment are early-stage with revenue far off.
Bottom line: The demand wave is genuine and policy-supported. BBAI's problem is not the pond — it is that its own programs are lumpy, its backlog is partly optional-component/IDIQ-ceiling dependent (per Iceberg), and it has a demonstrated history of guiding, missing, and restating. Treat the structural demand as real but BBAI's ability to proportionally capture it as unproven.
Multi-year SEC XBRL financials (revenue & net income).
Fair-value method: EV/Sales peer band (~8x-13x) applied to FY2025 revenue of $127.672M — a discount to Palantir's profitable-leader multiple and a premium to slow-growing primes (Booz Allen, Leidos) — divided by 477.014M shares. Illustrative, not precise; hinges on whether 2026 revenue re-accelerates. The current $5.04 sits above this band, reflecting narrative/meme premium.
A modeled estimate, not a price target, not advice.
## Positioning: Niche Participant in a Real but Crowded Pond
The pond is real and growing. US defense-AI software spending is a genuine multi-billion-dollar wave. Grand View Research pegs the US AI-in-military market at ~$2.0B in 2024, growing to ~$3.2B by 2030 at ~8.3% CAGR. The broader US AI-in-aerospace-and-defense market (Precedence Research) is ~$7.8B in 2024, heading to ~$20.5B by 2034 at ~10.1% CAGR. The FY2026 NDAA (signed 2025-12-18) authorized ~$146B in DoD RDT&E, and the administration's FY2026 budget request earmarked $13.4B for autonomy and AI-driven systems. This is a structural tailwind, not a manufactured one.
The fish problem. The pond has very large, well-capitalized fish:
Where BBAI sits. BBAI is a niche/small participant, not a leader — competing in a sub-segment of DoD decision intelligence, force management, biometrics, and supply-chain security. Its real differentiators: (1) the GFIM-OE Army franchise (5-year sole-source production award = genuine technical lock-in on one critical program); (2) Ask Sage (a GenAI platform with 100K+ government users on 16K teams = sticky distribution into national security); (3) CEO Kevin McAleenan's senior-federal access (former Acting DHS Secretary, CBP Commissioner).
The "good pond, bad fish" verdict: BBAI is in the right pond but is a small, unprofitable fish among much larger predators. It has real contracts and legitimate technology, but no pricing power, a thin moat outside specific existing program relationships, and no path to compete at Palantir's scale on commercial AI. Its best case is winning a cluster of sole-source or small-pool federal awards where incumbency and clearances matter more than brand. The risk is that primes (Booz Allen, Leidos, SAIC) sub it out or replace it on re-compete.
-
Company: BigBear.ai Holdings Inc (BBAI, NYSE) — AI-powered decision-intelligence / data-analytics software for US government, defense, and intelligence (plus some commercial). -
Price / market cap: $5.04 / ~$2.414B (fact sheet). -
Shares outstanding: 477,014,064 as of 2026-03-31. -
FY2025 revenue: $127.672M, down ~19% from FY2024 ($158.236M). -
FY2025 losses: operating -$213.897M; net -$293.914M (both larger than annual revenue). -
Rating: 3.1 / 10 — "Weak" — risk badge RED.
BigBear.ai builds AI/ML decision-intelligence software for national-security customers: force management (the GFIM-OE Army program), biometrics (via the Pangiam acquisition), geopolitical-risk and near-peer-adversary analysis (the CDAO/VANE prototype), and supply-chain/cargo security. A smaller commercial layer exists, and the December 2025 Ask Sage acquisition adds a GenAI-SaaS platform. The business is heavily program-dependent — revenue is lumpy and tied to specific government awards rather than a broad recurring product base.
Three planks: (1) convert backlog ($281.9M at Q1 2026) — especially the $53M sole-source classified prime award and the GFIM-OE production ramp — into recognized revenue; (2) scale Ask Sage (~$25M ARR, ~6x YoY) and upsell GenAI into the federal user base to add recurring, higher-margin revenue; (3) expand internationally (UAE office opened December 2025, AD Ports MOU January 2026) and commercially (Panama/ISC cargo security, first deployment May 2026). Management is led by CEO Kevin McAleenan (former Acting DHS Secretary / CBP Commissioner), appointed January 2025, whose senior-federal access is a genuine business-development asset.
Multi-year revenue (fact sheet): FY2019 $73.626M; FY2021 $145.578M; FY2022 $155.011M; FY2023 $155.164M; FY2024 $158.236M; FY2025 $127.672M. Essentially flat for three years, then a ~19% decline in 2025 — the lowest since the SPAC era.
Profitability (fact sheet): never GAAP-profitable as a public company. Operating income: -$39.034M (2023), -$133.420M (2024), -$213.897M (2025) — the operating loss WIDENED ~60% in 2025 even as revenue fell. Net income: -$70.657M (2023), -$295.547M (2024), -$293.914M (2025). The last GAAP-positive year was FY2019 (+$6.246M net on $73.626M revenue), pre-SPAC.
Cash flow & balance sheet (fact sheet): operating cash flow negative every year shown — -$19.782M (2021), -$48.918M (2022), -$18.307M (2023), -$38.119M (2024), -$41.951M (2025). Year-end cash rose to $87.126M (2025) from $50.141M (2024), and the Q1 2026 release cited ~$431.5M of total cash + investments — but that improvement is overwhelmingly proceeds from equity issuance and debt conversion, NOT organic cash generation.
Runway: on a pure operating-burn basis (~$42M/yr), the year-end $87.126M cash (2025) and the ~$431.5M Q1 2026 cash+investments give multiple years of runway — there is no going-concern language in the Q1 2026 release, so none is asserted here. The caveat: that runway exists because of dilution, not operations, and the cost base is expanding (the $140M cash portion of Ask Sage was also absorbed).
Share-count / dilution (fact sheet): 135.566M (end-2021) -> 127.022M (end-2022) -> 157.288M (end-2023) -> 251.554M (end-2024) -> 436.956M (end-2025) -> 477.014M (2026-03-31). Roughly a 3.5x expansion since end-2021 and ~3x since end-2023, still +~9% in a single quarter. Drivers: a $150M at-the-market equity program (Form 424B5, May 2025), up to $110M of stock in the Ask Sage deal, and conversion of convertible notes to equity.
At $5.04 the market cap is ~$2.414B on 477.014M shares. Against FY2025 revenue of $127.672M that is ~18.9x trailing sales; against the FY2026 guidance midpoint (~$150M) it is ~16.1x forward sales — growth-software multiples on a business whose revenue is FALLING and whose net loss exceeds its revenue. Profitable, faster-growing peers (Booz Allen ~$12B revenue; Leidos ~$15B revenue) trade at low-single-digit-to-low-double-digit revenue multiples; the only comp near BBAI's multiple is Palantir, which is GAAP-profitable and ~30x larger.
Fair-value range (transparent method): an EV/Sales peer band applied to the FY2025 revenue base of $127.672M, adjusted for BBAI's contraction and loss profile. A growth-but-lossmaking small-cap government-AI name might fairly carry ~8x-13x sales (a discount to Palantir's profitable-leader multiple, a premium to slow-growing primes). That implies roughly $1.02B-$1.66B of equity value, or ~$2.15-$3.48 per share on 477M shares. The current ~$5.04 sits above that band, reflecting narrative/meme premium rather than fundamentals; the sell side implicitly agrees (3-analyst "Hold," avg target $5.50, ~9% upside). Treat the range as illustrative, not precise — it hinges on whether 2026 revenue re-accelerates.
The dominant ownership signal is dilution behaviour: an open $150M ATM selling shares into the market, stock-funded M&A, and note conversions, tripling the share count in just over two years. A secondary source (Iceberg Research / StockTwits, NOT confirmable from the fact sheet) alleges that AEIP — the Pangiam-acquisition seller — sold 17.9M shares for ~$83.9M on 2025-03-03 to 2025-03-06, days before the Q4 2024 print that revealed the revenue decline; this timing is central to the class-action allegations. No major institutional sell-side conviction exists (thin coverage, "Hold" consensus). The Pangiam founders, including the CEO, remain significant holders.
The honest bull case is NOT "cheap asset" — at ~16-19x sales it is expensive — it is a pre-inflection bookings turn. (1) Bookings are turning even as recognized revenue lagged: backlog reached $281.9M, lifted by a $53M sole-source classified prime award on top of the $165.15M 5-year GFIM-OE Army franchise. (2) Ask Sage bolts a recurring GenAI-SaaS layer (~$25M ARR, ~6x YoY, 100K+ government users) onto a lumpy services book — the single most important re-rate lever. (3) The balance sheet is de-risked: ~$431.5M cash+investments (Q1 2026) against modest burn removes near-term dilute-or-die pressure. (4) A law-backed demand wave (FY2026 NDAA ~$146B RDT&E, $13.4B autonomy/AI) sits underneath. If BBAI simply returns to growth in 2026 and Ask Sage scales, the "secular decliner" framing breaks and a higher multiple can be applied to a larger base. Realistic upside is the analyst path (~$6, +~15-20%); the meme-driven double is optionality, not expectation, and Leidos-class takeout interest is a downside-floor option.
BBAI is a structurally unprofitable, flat-to-declining government-AI niche contractor priced like a growth company it has never been.
-
Revenue is shrinking, not growing (HIGH): $158.236M (2024) -> $127.672M (2025), a ~19% decline in the middle of the loudest defense-AI wave; Q1 2026 still -1% YoY. The entire bull narrative is growth; the audited numbers show contraction. -
Losses exceed revenue (HIGH): FY2025 operating loss -$213.897M (widened from -$133.420M in 2024) and net loss -$293.914M on $127.672M revenue. No demonstrated operating-leverage path to profitability. -
Relentless dilution (HIGH): ~3.5x share-count expansion in ~4 years, still +~9% in Q1 2026; open ATM; the "strong balance sheet" IS the dilution. -
Persistent cash burn funded by capital markets (HIGH): five straight years of negative operating cash flow (-$41.951M in 2025); liquidity is financing-dependent, not earnings-dependent. -
Rich valuation on a shrinking, lossmaking base (HIGH): ~18.9x trailing sales; the "next Palantir" retail framing is unsupported. -
Accounting restatement + two securities class actions (HIGH): a March 2025 disclosure of a material error (ASC 815-15 convertible-note bifurcation) forced a restatement back to FY2021; Priewe v. BigBear.ai (E.D. Va.) and Weiss v. BigBear.ai (S.D.N.Y.) are pending. Material, unquantified liability and an integrity-of-numbers flag. -
Insider/large-holder selling before bad news (HIGH, secondary-sourced): the ~$83.9M AEIP sale ahead of the Q4 2024 print — flagged as Iceberg/StockTwits-sourced, not from the fact sheet. -
Promotional PR pattern (MEDIUM): ceiling values (the $2.4B FAA IDIQ shared across 14 awardees), MOUs, and a re-framed prototype (CDAO/VANE) presented as wins; SPAC heritage (GX Acquisition Corp. II, Dec 2021) compounds the profile. -
Backlog quality (MEDIUM): Iceberg alleges the 2023->2024 backlog jump was "mostly optional contract components, not firm commitments." -
Extreme meme/speculation behaviour (MEDIUM): ~$0.67 -> $10.36 52-week run then retrace; beta ~4.19. Price action detached from fundamentals.
What must be true for the bull case: 2026 revenue must actually re-accelerate to the upper half of guidance and show YoY growth; backlog (the $53M classified award, GFIM-OE) must convert rather than stay optional; Ask Sage must scale and integrate; operating losses must inflect toward breakeven; dilution must slow dramatically; and the restatement/litigation overhang must resolve at a manageable cost. That is a lot that must go right at once.
Open questions: Does the $53M classified award and GFIM-OE ramp show up in H2 2026 revenue? Does Ask Sage ARR lift consolidated growth and gross margin? Does the ATM finally taper now that the balance sheet is funded? What is the settlement exposure on the class actions?
Classification: Cash-burning thematic defense-AI bet — a high-beta speculation vehicle, not a margin-of-safety setup.
Confidence: Moderate. The deterministic financials (decline, losses, dilution, burn) are high-confidence from EDGAR; several risk items (concentration %, insider-sale specifics, restatement reaction) are secondary-sourced and flagged as such; the forward inflection is an unproven bet.
Research, not investment advice. Figures sourced from SEC filings and public data; verify before acting.
Smart-money read is negative: relentless company-driven dilution (open ATM + stock-funded M&A + note conversions tripling the share count) and secondary-sourced large-holder selling ahead of bad news, against thin, lukewarm institutional coverage ('Hold,' ~9% upside) — no conviction buyer on the other side.
Research, rating, fair value & financials are as of the analysis on May 31, 2026. Generated by claude-opus-4-8 (catalyst dogfood). Not investment advice.